Clinical trials - Press Releases

Date	Title	Company
24-Mar-2021	TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020	TOT BIOPHARM
23-Mar-2021	TrialWire launches StudyBoost, the Clinical Trial Insurance Plan	TrialWire
23-Mar-2021	RECORDATI RARE DISEASES: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED TODAY AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE	Recordati Rare Diseases
22-Mar-2021	AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis	AstraZeneca
19-Mar-2021	Resistance-busting ICR drug enters clinical trial	The Institute of Cancer Research, London
18-Mar-2021	Invite from Justin Mason-Home, Chair at SMi’s 5th Annual Highly Potent Active Pharmaceutical Ingredients 2021	SMi Group
18-Mar-2021	$15 million for development of innovative therapies for mental illness	Department of Health Australia
18-Mar-2021	Gilead Sciences and Novo Nordisk expand NASH clinical collaboration	Novo Nordisk
17-Mar-2021	Invitation from Michael Scherz and Naheed Mirza, Co-Chairs at Pain Therapeutics 2021	SMi Group
17-Mar-2021	Immutep Enters Second Collaboration with MSD For a New Randomised Phase IIB Trial in Head and Neck Cancer	Immutep
17-Mar-2021	Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study	Lilly
16-Mar-2021	Data From Phase 3 Extension Study Show TREMFYA®▼ (guselkumab) Maintains Joint Efficacy and Complete Skin Clearance in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years	Janssen
16-Mar-2021	PCI Broadens Clinical Trial Service Offerings at Berlin Facility	PCI Pharma Services
16-Mar-2021	Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson’s disease patients	Newron Pharmaceuticals S.p.A.
16-Mar-2021	Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients	SOUTH PLAINFIELD
16-Mar-2021	Pistoia Alliance Survey Finds 62 Percent of Life Science Professionals say AI will Lead to Faster R&D, but is Held Back by Skills Gap and Data Bias	The Pistoia Alliance
16-Mar-2021	New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)	Roche
16-Mar-2021	Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)	Takeda
15-Mar-2021	Gore REDUCE Clinical Study Five-Year Results Demonstrate That PFO Closure With The GORE® CARDIOFORM Septal Occluder Provides Safe Long-Term Reduction Of Recurrent Stroke	W. L. Gore & Associates
15-Mar-2021	Antigen Skin Test Market 2021: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2026	ARC Report Stores